@article{ShityakovNagaiErguenetal.2022,
  author    = {Shityakov, Sergey and Nagai, Michiaki and Erg{\"u}n, S{\"u}leyman and Braunger, Barbara M. and F{\"o}rster, Carola Y.},
  title     = {The protective effects of neurotrophins and microRNA in diabetic retinopathy, nephropathy and heart failure via regulating endothelial function},
  series = {Biomolecules},
  volume    = {12},
  journal   = {Biomolecules},
  number    = {8},
  issn      = {2218-273X},
  doi       = {10.3390/biom12081113},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-285966},
  year      = {2022},
  abstract  = {Diabetes mellitus is a common disease affecting more than 537 million adults worldwide. The microvascular complications that occur during the course of the disease are widespread and affect a variety of organ systems in the body. Diabetic retinopathy is one of the most common long-term complications, which include, amongst others, endothelial dysfunction, and thus, alterations in the blood-retinal barrier (BRB). This particularly restrictive physiological barrier is important for maintaining the neuroretina as a privileged site in the body by controlling the inflow and outflow of fluid, nutrients, metabolic end products, ions, and proteins. In addition, people with diabetic retinopathy (DR) have been shown to be at increased risk for systemic vascular complications, including subclinical and clinical stroke, coronary heart disease, heart failure, and nephropathy. DR is, therefore, considered an independent predictor of heart failure. In the present review, the effects of diabetes on the retina, heart, and kidneys are described. In addition, a putative common microRNA signature in diabetic retinopathy, nephropathy, and heart failure is discussed, which may be used in the future as a biomarker to better monitor disease progression. Finally, the use of miRNA, targeted neurotrophin delivery, and nanoparticles as novel therapeutic strategies is highlighted.},
  language  = {en}
}
@article{ShityakovHayashiStoerketal.2021,
  author    = {Shityakov, Sergey and Hayashi, Kentaro and St{\"o}rk, Stefan and Scheper, Verena and Lenarz, Thomas and F{\"o}rster, Carola Y.},
  title     = {The conspicuous link between ear, brain and heart - Could neurotrophin-treatment of age-related hearing loss help prevent Alzheimer's disease and associated amyloid cardiomyopathy?},
  series = {Biomolecules},
  volume    = {11},
  journal   = {Biomolecules},
  number    = {6},
  issn      = {2218-273X},
  doi       = {10.3390/biom11060900},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-241084},
  year      = {2021},
  abstract  = {Alzheimer's disease (AD), the most common cause of dementia in the elderly, is a neurodegenerative disorder associated with neurovascular dysfunction and cognitive decline. While the deposition of amyloid β peptide (Aβ) and the formation of neurofibrillary tangles (NFTs) are the pathological hallmarks of AD-affected brains, the majority of cases exhibits a combination of comorbidities that ultimately lead to multi-organ failure. Of particular interest, it can be demonstrated that Aβ pathology is present in the hearts of patients with AD, while the formation of NFT in the auditory system can be detected much earlier than the onset of symptoms. Progressive hearing impairment may beget social isolation and accelerate cognitive decline and increase the risk of developing dementia. The current review discusses the concept of a brain-ear-heart axis by which Aβ and NFT inhibition could be achieved through targeted supplementation of neurotrophic factors to the cochlea and the brain. Such amyloid inhibition might also indirectly affect amyloid accumulation in the heart, thus reducing the risk of developing AD-associated amyloid cardiomyopathy and cardiovascular disease.},
  language  = {en}
}